Why the study?
Does a genetic variant in the human apo CIII promoter abolish regulation by insulin?
Does a genetic variant in the human apo CIII promoter abolish regulation by insulin?
A common genetic variant in the human apo CIII promoter abolishes its downregulation by insulin, providing a molecular mechanism that may contribute to the development of hypertriglyceridemia.
May contribute to hypertriglyceridemia; hypothesis-generating in animal models, human validation required.
Overexpression of plasma apolipoprotein CIII (apo CIII) causes hypertriglyceridemia in transgenic mice. A genetically variant form of the human apo CIII promoter, containing five single base pair changes, has been shown to be associated with severe hypertriglyceridemia in a patient population. In animals and in cultured cells the apo CIII gene is transcriptionally downregulated by insulin. In this study we demonstrate that, unlike the wild-type promoter, the variant promoter was defective in its response to insulin treatment, remaining constitutively active at all concentrations of insulin. The loss of insulin regulation was mapped to polymorphic sites at -482 and -455, which fall within a previously identified insulin response element. Loss of insulin regulation could result in overexpression of the apo CIII gene and contribute to the development of hypertriglyceridemia. The variant apo CIII promoter is common in the human population and may represent a major contributing factor to the development of hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Li et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: